Published in Pharma Law Weekly, November 22nd, 2005
AMD is the leading cause of legal blindness effecting more than 50 million people worldwide. Currently there is no effective treatment for dry AMD.
TheraMac has already successfully completed a proof of concept U.S. Food and Drug Administration (FDA) trial which showed that in 2 weeks 26% of the eyes treated had improved vision by 10 letters or more, the equivalent of two lines on the eye chart. TheraMac has also been the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly